Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Ultrasound
  6. 1st Trimester Screening for Trisomy 21 (T21), Trisomy 18 (T18), Trisomy 13 (T13) in Singleton pregnancies: Nuchal Translucency (NT) Scan (499)
RDS newsletter for February now available

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

1st Trimester Screening for Trisomy 21 (T21), Trisomy 18 (T18), Trisomy 13 (T13) in Singleton pregnancies: Nuchal Translucency (NT) Scan (499)

Warning

Please report any inaccuracies or issues with this guideline using our online form

Appointments for a dating scan including 1st trimester screening for Down’s, Edwards’ and Patau’s Syndrome (NT measurements) should be no less than 25 minutes. This should include time to get “on and off the couch”, time to perform the ultrasound examination and time to complete the report.

All Sonographers performing NT measurements must be appropriately trained and accredited and their results subjected to rigorous audit and performance management. To assure continuing satisfactory performance each Sonographer must perform a minimum of 25 nuchal translucency measurements every 6 months and have DQASS ‘Green’ or ‘Amber’ flag status.

The ultrasound equipment used must meet NSC FASP specifications. It should have a cineloop function and calliper precision to one decimal point i.e. 0.1mm. Operators should be aware of and adhere to BMUS guidelines for safe use of ultrasound including exposure times.

The screening period is between 11+2 to 14+1 weeks gestation. The scan will be targeted at a gestation of approx 12 weeks. The scan can be performed by the transabdominal or transvaginal route.

Consent

Sonographers must ensure formal consent has been obtained. Check the details of the booking on the ‘antenatal assessment’ tab on Badger net under ‘screening and scans offered/accepted or declined'.

Women can chose to have screening for T21 syndrome only or to have screening for T21, T18 & T13. It is not possible to have screening for T18 and/or T13 without screening for T21.

Prior to beginning scan, give a brief explanation of the scan, including limitations and obtain verbal consent to continue.

If consent for 1st trimester screening is not obtained a “dating” scan only should be performed. The Sonographer should also advise that if an increased NT ≥ 3.5mm is detected, this can be indicative of a structural abnormality and would require referral to a Medical Sonographer.

The Ultrasound Examination

Where both dating and 1st trimester screening are requested and the CRL is between 45.0 and 84.0mm, the pregnancy should be dated using the CRL measurement.

Criteria for measurement of the fetal crown rump length (CRL) as part of the combined 1st trimester screening programme

The CRL range should be between 45.0 and 84.0 mm.

The magnification of the fetus should be as large as possible clearly demonstrating the entire crown-rump length.

A midline sagittal section of the whole fetus should be obtained with the fetus horizontal on the screen, either supine or prone. The fetus should be in a neutral position with fluid visible between the fetal chin and chest, neither hyper extended nor flexed.

The best of three measurements should be taken. Linear callipers should be used to measure the maximum un-flexed length. Intersection of the callipers (+) should be placed on the outer margin of the skin borders of the CRL. Two images of the measured CRL must be retained, one for the patient record and one for audit purposes.

If the CRL is < 45.0mm re-appoint the patient within the 11+2 – 14+1 weeks screening window.

If the CRL is > 84.0mm arrange appointment for 2nd trimester biochemistry screening and date pregnancy using Head Circumference (HC).

The NT Measurement

The NT measurement should only be performed if a CRL measurement, which meets the recommended NHS FASP criteria for CRL has been obtained.

Criteria for measurement of the fetal nuchal translucency (NT) measurement

A midline sagittal section of the fetus should be obtained. The fetus should be horizontal on the screen, either supine or prone.

Care must be taken to distinguish between fetal skin and amnion. The fetus should be in a neutral position.

The image should be magnified, such that only the fetal head and upper thorax occupy the whole screen. In magnifying the image (pre- or post-zoom) it is important to turn down the gain.

The widest part of the translucency must always be measured. Measurements should be taken with the horizontal lines of the callipers placed ON the lines that define the NT thickness.

During the scan more than one measurement must be taken and the maximum one which meets all the criteria should be recorded. Two images of this measured NT should be retained, one for the patient record, one for audit purposes.

If the NT measurement is ≥ 3.5mm, perform combined screening test and follow pathway for raised nuchal translucency (NT) ≥ 3.5mm

Too early/late/unable to obtain measurements

Too Early: CRL measurement <45.0mm – re-appoint at appropriate gestation.

Too late: CRL measurement >84.0mm – arrange appointment for 2nd trimester biochemistry (≥ 15+0 weeks) screening and date pregnancy using Head Circumference (HC).

Unable to obtain measurements – offer a 2nd attempt. This second attempt at screening should be on the same day.

If unable to obtain measurements after two attempts, explain limitations of scan and record on report. Arrange 2nd trimester dating scan to coincide with biochemistry appointment.

Ultrasound Images

One set of paired CRL and NT images to be inserted into brown image envelope in patient notes, one set to be kept aside for audit purposes.

Ultrasound Report

The Ultrasound report should be documented on Badgernet under ‘Key Notes – New Ultrasound Note’. Ensure all appropriate fields are filled including the authorization box (your digital signature) for the report to be valid.

If unable to obtain NT measurements indicate reason for failed attempt i.e. poor views due to fetal position. If patient to be re-appointed for 2nd trimester screening enter suggested date.  

Medical Genetics Form (Appendix A)

Attach a patient label, with name, address, DOB and CHI number to the Medical Genetics First Trimester Combined Ultrasound and Biochemical (CUB) Screening form.

Enter the following data:

  • Hospital
  • Consultant
  • Maternal Weight
  • Number of Fetuses
  • Chorionicity if multiple pregnancy
  • Maternal Family Origin

Indicate YES or NO for the following categories:

  • Screening required – Down’s Syndrome T21
  • Screening required – Edwards’ Syndrome T18 and Patau’s Syndrome T13
  • Current Smoker
  • Previous Trisomy Pregnancy
  • IDDM

Complete the Ultrasound Details section;

  • Date of scan
  • Estimated date of delivery
  • CRL (mm)
  • NT (mm)
  • Ultrasonographer code

If assisted conception pregnancy, record all relevant details in the Assisted Conception section

“Date of sample” and “Sample taken by” fields to be entered by the Midwife/HCSW who performs the venipuncture.

Medical Genetics form to be passed to the Midwife/HCSW for completion and sent together with the biochemistry sample to Medical Genetics Labs.

Appendix A - Medical Genetics Form

Medical Genetics, First Trimester Combined Ultrasound and Biochemical (CUB) Screening Form.

 

Editorial Information

Last reviewed: 03/05/2024

Next review date: 04/05/2028

Author(s): Donna Bean.

Version: 3

Co-Author(s): Alan Mathers.

Approved By: Maternity Governance Group

Document Id: 499